Skip to main content
  1. Home
    /
  2. IPO
    /
  3. Gaudium IVF & Women Health IPO
Gaudium IVF & Women Health IPO
7.22xsubscribed

Gaudium IVF & Women Health IPO

Hospital & Healthcare Services
listed
₹14,175Min. investment

Gaudium IVF & Women Health Limited IPO Details

SectorHospital & Healthcare Services
Price range₹75.00 – ₹79.00
IPO type
Regular
Lot size189 shares
Issue size₹165Cr
Red Herring Prospectus
Read
Market cap
₹575CrLower than sector avg
RevenueApr 2024 - Mar 2025
₹70.72CrLower than sector avg
Growth rate3Y CAGR
26.43%

Gaudium IVF & Women Health IPO Subscription Status

Date
QIB
NII
Retail
Total
20-Feb-26
0.0 times (X)
0.91 times (X)
1.39 times (X)
0.89 times (X)
23-Feb-26
0.02X
4.59X
4.03X
3.01X
24-Feb-26
0.94X
13.98X
7.51X
7.22X

As on 20-Feb-26, 5:30 PM

Gaudium IVF & Women Health IPO Timeline

  1. Pre-apply
    18 Feb 2026
  2. Bid start
    20 Feb 2026
  3. Bid end
    24 Feb 2026
  4. Allotment
    25 Feb 2026
  5. Release of funds
    25 Feb 2026
  6. Demat transfer
    26 Feb 2026
  7. Listing
    27 Feb 2026

About Gaudium IVF & Women Health Limited

Incorporated in 2015, Gaudium IVF and Women Health provide IVF and women health services throughout India. The company has developed its operations across different states through a hub-and-spoke system. It provides multiple fertility treatments, which include IVF, ICSI, IUI and ovulation induction to assist men and women who experience infertility challenges. The organisation provides treatment for multiple health conditions, which include PCOS/PCOD, endometriosis and high-risk pregnancy situations. It also provides multiple services, which include advanced sperm retrieval for male infertility treatment, egg freezing and laparoscopic and hysteroscopic surgeries and genetic testing (PGT) and medical support for surrogacy.
The company operates more than 30 locations, which include 7 main centres (hubs) and 28 partner clinics (spokes) through its collaboration with infertility specialists to promote knowledge about IVF and assisted reproductive treatments. Its main centres operate from multiple Indian cities, which include Delhi, Mumbai, Ludhiana, Srinagar, Patna, and Bangalore. The company operates a 15-bed hospital at its Janakpuri centre in Delhi NCR, which specialises in mother and child care.
IVF treatments generated the highest revenue share, which reached 68.6% or ₹33.9 crore, while the hospital services generated a smaller revenue share of 2.6% or ₹1.29 crore as of H1FY26. The pharmacy, which contributed 28.85% of revenue, operates through its subsidiary, which delivers medical supplies and products to various locations from its Janakpuri facility.
The company also provides treatments to international patients from countries like Canada, the United Kingdom, the United States, Kenya, South Africa, and Oman. The organisation provided medical services to 76 international patients during H1FY26, with the majority of patients coming from the UK, USA and Canada. The company established a collaborative agreement with a London-based partner on May 1 2024. The partner organisation provides IVF consulting services to guide patients while receiving 25% of treatment fees, which result from patient referrals. The company has achieved an embryo transfer success rate of 58.7% during H1FY26. The period of 509 embryo transfers led to 299 successful pregnancies. The company performed 1,824 treatment cycles during H1FY26. The company employed 122 workers throughout its centres as of September 2025, which included doctors and nurses, embryologists and counselors and administrative personnel. The attrition rate was 31% during H1FY26, compared to 63% in FY25 and 51% in both FY24 and FY23.
The Indian IVF market size is projected to grow from $1.32 billion in 2024 to $4.54 billion by 2034, with a CAGR of 13.13%. The share of India in the global IVF market is planned to increase from around 4.8% in 2024 to 8.3% by 2034, thus placing it among the top fastest, growing IVF markets worldwide. The business has shown steady operational results, with 3,512 cycles in FY23, 3,711 cycles in FY24, 3,476 cycles in FY25, and 1,824 cycles as of September 30, 2025.
The company plans to expand its hub-and-spoke model across India. The plan is for different kinds of IVF, IUI, and embryo transfer at major hub centres, which are located in big cities, while smaller spoke centres will mainly do consultation, basic treatment, and follow-up activities near the patient's home. This plan is to facilitate better access to quality fertility services in the abandoned areas, to keep service standards uniform at all locations, to make medical resources available more efficiently, and to have a strong internal referral network. Now, Gaudium IVF & Women Health Ltd is launching its initial public offering (IPO), which consists of a fresh issue of ₹90 crore and an offer for sale of ₹75 crore. The total issue size of the IPO is ₹165 crore. Its shares will be listed on the NSE and BSE.
How to apply for the Gaudium IVF & Women Health IPO?
If you are interested in this investment opportunity but unsure how to apply for the Gaudium IVF & Women Health IPO, here are the steps that you need to follow.
When the public issue opens for subscription, one can follow this step-by-step guide on how to apply for the Gaudium IVF & Women Health IPO on Upstox:
  • Log in to your Upstox account, using your six-digit PIN
  • After logging in, click on ‘Discover’
  • On the ‘Discover’ tab, you will find the ‘Invest in IPO’ section
  • Under the Invest in IPO section, look for the ‘Gaudium IVF & Women Health IPO’ tab and click on it
  • Now fill in all the required information, like ‘bid price’ and ‘lot size’
  • Confirm and click on ‘Apply’
  • Accept the mandate on your UPI app

**How to check Gaudium IVF & Women Health IPO Allotment Status? **

When the allotment process is completed, you can check the status of your application on the Upstox app. Share allotment is generally completed on the next working day after an IPO closes.
Here’s a step-by-step guide on how to check the Gaudium IVF & Women Health IPO allotment status:
  • Login to your Upstox account, using your six-digit PIN
  • After logging in, click on ‘Discover’
  • On the ‘Discover’ page, you will find the ‘Invest in IPO’ section
  • Under the Invest in IPO section, you will find the ‘View all’ option
  • Once you click on ‘View all’, you will be directed to the ‘IPO’ tab
  • In the ‘IPO’ tab, click on ‘My applications’
  • In ‘My applications’, under the History section, your Gaudium IVF & Women Health IPO allotment status will be mentioned

How to pre-apply for the Gaudium IVF & Women Health IPO?

You can pre-apply for the Gaudium IVF & Women Health IPO on Upstox. The pre-application for this IPO, which means the pre-apply open date, usually begins a day before the IPO opens for subscription.
Follow these steps to pre-apply for the IPO:
  • Login to your Upstox account, using your six-digit PIN
  • After successfully logging in, click on ‘Discover’
  • On the Discover tab, you will find the ‘Invest in IPO’ section
  • Under the Invest in IPO section, look for the ‘Gaudium IVF & Women Health IPO’ tab and click on it
  • Now fill in all the required information, like ‘bid price’ and ‘lot size’
  • Confirm and click on ‘Pre-Apply’
  • Accept the mandate on your UPI app

Gaudium Ivf And Women Health IPO Analysis

IPO REVIEW

Gaudium IVF & Women Health IPO | Analysis Video

Should you apply?

Watch our analysts break down the Gaudium Ivf And Women Health IPO — business model, financials, valuation and key risks — to help you decide whether to apply. The video covers the IPO price band, important dates, and what the subscription numbers mean for retail investors.

Checklist

Quality analysis
Revenue growth
Company valuation
Earnings expansion
Risk analysis
Debt to Equity ratio
Promoter holdings
Shares pledged
The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily

Strength and Weakness

Pan-india network scale

Gaudium IVF operates a pan-India fertility platform with 30+ locations, comprising 7 hubs and 28 spokes. The hubs are strategically located across Delhi (2), Mumbai, Bengaluru, Patna, Ludhiana and Srinagar, while spokes extend reach across 10+ states. This hub-and-spoke model centralises high-complexity ART procedures while spokes drive patient acquisition and follow-ups, improving throughput and cost efficiency.

Capital-light and scalable operating model

The company follows an asset-light operating structure, with centres largely housed in leased facilities. Each hub is designed with 5 to 15 beds and a single operating theatre, enough to handle IVF volumes efficiently. This keeps fixed costs under control, enables quicker breakeven for new centres, and supports growth without putting pressure on the balance sheet.

Proprietary genome-based GAAT platform

Gaudium IVF has developed its own GAAT (Gaudium Advanced Analysis and Treatment) platform, a genome-based IVF approach aimed at patients with complex fertility challenges such as repeated IVF failures or advanced maternal age. By combining genetic insights from the female partner, male partner and embryos, GAAT helps doctors personalise treatment plans. Development costs of ₹7.38 crore have been capitalised as of March 31, 2025, with no royalty obligations, strengthening IP ownership.

Comprehensive high-complexity ART services

Gaudium IVF offers a full spectrum of ART services, including IVF, ICSI, IMSI, IUI, TESA, cryopreservation and embryo transfer. The company treats complex conditions such as PCOS, endometriosis, azoospermia, and recurrent implantation failure. Advanced procedures like IMSI and TESA, which typically command higher realisations, support revenue per cycle and clinical differentiation.

Advanced technology and precision diagnostics

Gaudium IVF employs next-generation embryology labs with INTEGRA Tiâ„¢ platforms for ICSI, advanced egg quality evaluation systems, and Samsung ultrasound machines for precise clinical monitoring. The company also offers highly technical USG-guided procedures, including HSG, transvaginal and transrectal scans, follicular monitoring, biopsies, and ovarian cyst aspiration. This technological depth allows for precise diagnosis and better decision-making in complex fertility cases.

Objectives of Gaudium Ivf And Women Health IPO

Capital expenditure
55.50%
The company will use approximately ₹50 crore for the establishment of new IVF Centers.
General corporate purposes
22.30%
Part of the IPO proceeds will be used for general corporate purposes and issue expenses
Repayment of borrowings
22.20%
The company will use ₹20 crore for repayment of certain outstanding loans availed by it.

Compare

CompanyRevenue*3Y growthMarket capP/E ratioD/E ratio
This IPO₹70.72Cr26.43%₹575Cr25.320.41
This sector (avg.)₹810.55Cr---₹10,075.9Cr55.140.40
₹21,794Cr---₹1,00,081.3Cr59.860.96
₹7,028.46Cr---₹93,096.78Cr68.940.32
₹7,782.75Cr---₹64,284.69Cr63.430.28

*Revenue for financial year 2024-25. Lower P/E and D/E ratios are generally preferred.

Gaudium IVF & Women Health IPO Contact Details

Company NameGaudium IVF & Women Health Limited

How to apply for Gaudium IVF & Women Health IPO?

  1. Step 1

    Log in to your Upstox account to access IPO investments. Next, select the current IPO section.

  2. Step 2

    Specify IPO details. Enter the number of lots and the price you wish to apply for.

  3. Step 3

    Enter UPI ID. After entering your UPI ID, click submit. This will place your bid with the exchange.

  4. Step 4

    Mandate Notification. Your UPI app will receive a mandate notification to block funds.

  5. Step 5

    Approve Request. Your funds will be blocked once you approve the mandate request on your UPI.

Gaudium Ivf And Women Health IPO FAQs

Investors can apply for the Gaudium IVF & Women Health IPO through their Demat account via the stock exchange or through their broker.
The issue size of the Gaudium IVF & Women Health IPO is 165 Cr.
Pre-applying for an IPO allows you to submit your application before the official subscription period begins.
The IPO shares will typically list on major stock exchanges such as the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE), as specified in the IPO prospectus.
Gaudium IVF & Women Health IPO will be open between 2026-02-20 and 2026-02-24.
Gaudium IVF & Women Health IPO allotment date is 2026-02-26. For Gaudium IVF & Women Health IPO allotment status check, you can visit the website of the registrar of the IPO.
For Gaudium IVF & Women Health IPO, the IPO registrar is Bigshare Services Private Limited. You can check Gaudium IVF & Women Health IPO allotment status on the website of the registrar.
The shares are proposed to be listed on the BSE and NSE.
The Gaudium IVF & Women Health IPO shares will typically be credited to your demat account one working day before the IPO's listing date, provided your application is successfully allotted.
The Gaudium IVF & Women Health IPO lot size is 189 and minimum order quantity is 189.
Gaudium IVF & Women Health IPO has set the price band for its IPO at 79 per equity share with a face value of 5.